Literature DB >> 25806165

INFORM; C-TONG 0805: A multicenter, double blind randomized phase III trial of maintenance gefitinib compared to placebo in advanced non-small cell lung cancer.

Thomas E Stinchcombe1.   

Abstract

Entities:  

Year:  2012        PMID： 25806165      PMCID： PMC4367578          DOI： 10.3978/j.issn.2218-6751.2012.06.03

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  13 in total

1.  Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.

Authors:  I E Smith; M E O'Brien; D C Talbot; M C Nicolson; J L Mansi; T F Hickish; A Norton; S Ashley
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

2.  Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.

Authors:  Li Zhang; Shenglin Ma; Xiangqun Song; Baohui Han; Ying Cheng; Cheng Huang; Shujun Yang; Xiaoqing Liu; Yunpeng Liu; Shun Lu; Jie Wang; Shucai Zhang; Caicun Zhou; Xiangwei Zhang; Nobuya Hayashi; Mengzhao Wang
Journal:  Lancet Oncol       Date:  2012-04-17       Impact factor: 41.316

3.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

4.  Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.

Authors:  Primo N Lara; Mary W Redman; Karen Kelly; Martin J Edelman; Stephen K Williamson; John J Crowley; David R Gandara
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

5.  Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).

Authors:  M Reck; J von Pawel; P Zatloukal; R Ramlau; V Gorbounova; V Hirsh; N Leighl; J Mezger; V Archer; N Moore; C Manegold
Journal:  Ann Oncol       Date:  2010-02-11       Impact factor: 32.976

6.  Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer.

Authors:  Joon Oh Park; Sang-We Kim; Jin Seok Ahn; Cheolwon Suh; Jung Shin Lee; Joung Soon Jang; Eun Kyung Cho; Sung Hyun Yang; Jin-Hyuk Choi; Dae Seog Heo; Suk Young Park; Sang Won Shin; Myung Ju Ahn; Jong Seok Lee; Young Ho Yun; Jae-Won Lee; Keunchil Park
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

7.  American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.

Authors:  Christopher G Azzoli; Sherman Baker; Sarah Temin; William Pao; Timothy Aliff; Julie Brahmer; David H Johnson; Janessa L Laskin; Gregory Masters; Daniel Milton; Luke Nordquist; David G Pfister; Steven Piantadosi; Joan H Schiller; Reily Smith; Thomas J Smith; John R Strawn; David Trent; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

8.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Authors:  Robert Pirker; Jose R Pereira; Aleksandra Szczesna; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Ihor Vynnychenko; Keunchil Park; Chih-Teng Yu; Valentyn Ganul; Jae-Kyung Roh; Emilio Bajetta; Kenneth O'Byrne; Filippo de Marinis; Wilfried Eberhardt; Thomas Goddemeier; Michael Emig; Ulrich Gatzemeier
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321

9.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

Authors:  Edward S Kim; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-Yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard
Journal:  Lancet       Date:  2008-11-22       Impact factor: 79.321

10.  Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.

Authors:  C von Plessen; B Bergman; O Andresen; R M Bremnes; S Sundstrom; M Gilleryd; R Stephens; J Vilsvik; U Aasebo; S Sorenson
Journal:  Br J Cancer       Date:  2006-10-03       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.